The SLC17A (solute carrier family 17) family comprises a group of membrane transport proteins that play key roles in the transport of a variety of substrates, including organic anions, phosphates, and neurotransmitters. Members of this family are primarily known as phosphate transporters (SLC17A1-4) and vesicular glutamate transporters (VGLUTs, SLC17A5-7). The phosphate transporters are involved in the renal reabsorption of phosphate, a critical process for maintaining phosphate homeostasis, bone mineralization, and overall metabolic function. The VGLUTs are crucial in the central nervous system, where they transport glutamate into synaptic vesicles, facilitating excitatory neurotransmission. The signaling and function of SLC17A transporters are essential in various physiological processes, from bone health to nerve communication, and their dysfunction is implicated in several diseases, including neurological disorders and phosphate metabolism abnormalities.
Targeting SLC17A signaling for disruption or inhibition with small molecules enables a more detailed understanding of the diverse roles these transporters play in physiological and pathological processes. By inhibiting specific SLC17A transporters, researchers can delineate their individual contributions to phosphate homeostasis and neurotransmitter regulation. Such targeted approaches are crucial in elucidating the mechanisms of diseases related to phosphate imbalance or glutamate signaling disorders. Additionally, the use of small molecule inhibitors can shed light on the potential targets within the SLC17A family for conditions like osteoporosis or neurodegenerative diseases.
Items 11 to 20 of 23 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Sofosbuvir | 1190307-88-0 | sc-482362 | 25 mg | $143.00 | 1 | |
外 ATP 酶抑制剂,可能会改变细胞外 ATP 水平,间接影响 SLC17A。 | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $92.00 $348.00 | 46 | |
它是一种质子诱导剂,能破坏质子梯度,从而可能影响 SLC17A 的功能。 | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $31.00 | 3 | |
非甾体抗炎药可能会间接影响离子通道和转运体(如 SLC17A)。 | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $27.00 $38.00 $98.00 $272.00 | 28 | |
竞争性抑制各种阴离子转运蛋白,从而可能降低SLC17家族成员的功能。 | ||||||
Phloridzin dihydrate | 7061-54-3 | sc-215708 sc-215708A | 250 mg 1 g | $48.00 $117.00 | ||
抑制钠依赖性转运体,可能会减少磷酸盐的竞争性吸收。 | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
非选择性地抑制各种膜蛋白,可能会改变与 SLC17A 有关的转运蛋白。 | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
通过影响前列腺素合成间接抑制阴离子转运体,改变肾脏转运动力学。 | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $40.00 | ||
抑制 NKCC2 的环利尿剂会对磷酸盐转运产生副作用。 | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $107.00 $224.00 | 9 | |
与呋塞米相似,可抑制 NKCC2,从而间接影响 SLC17A 的活性。 | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
影响肌醇单磷酸酶,导致阴离子转运发生变化,可能改变 SLC17A 的功能。 |